SCHEMBL21943534

SCHEMBL21943534

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1Oc1cc(-c2cccnc2)nc2c1ccn2C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 5/20 0.58
▸ DDR1 Q08345 5/20 0.58
▸ DDR2 Q16832 5/20 0.58
▸ ABL1 P00519 5/20 0.58
▸ BCR P11274 5/20 0.58
▸ BRAF P15056 4/20 0.58
▸ MAPK14 Q16539 3/20 0.58
▸ YES1 P07947 3/20 0.58
▸ ESYT2 A0FGR8 2/20 0.58
▸ NBAS A2RRP1 2/20 0.58
▸ CNOT1 A5YKK6 2/20 0.58
▸ TBKBP1 A7MCY6 2/20 0.58
▸ AGPS O00116 2/20 0.58
▸ MYO1F O00160 2/20 0.58
▸ SNAP23 O00161 2/20 0.58
▸ AP3B1 O00203 2/20 0.58
▸ PSMD12 O00232 2/20 0.58
▸ BMPR1B O00238 2/20 0.58
▸ PGRMC1 O00264 2/20 0.58
▸ CLIC1 O00299 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21943517 0.94 TEK (0.57) KDRDDR1DDR2ABL1BCR
SCHEMBL21943451 0.92 KDR (0.58) KDRDDR1DDR2ABL1BCR
SCHEMBL21943070 0.89 MEN1 (0.53) KDRDDR1DDR2ABL1BCR
SCHEMBL21943735 0.88 BRAF (0.51) KDRDDR1DDR2ABL1BCR
SCHEMBL21943013 0.87 MAPK14 (0.54) KDRDDR1DDR2ABL1BCR
SCHEMBL22024696 0.87 ABL1 (0.67) KDRDDR1DDR2ABL1BCR
SCHEMBL21943519 0.86 CSF1R (0.54) KDRDDR1ABL1BCRBRAF
SCHEMBL21943532 0.85 PIKFYVE (0.68) KDRDDR1DDR2ABL1BCR
SCHEMBL21943638 0.84 BRAF (0.54) KDRDDR1DDR2ABL1BCR
SCHEMBL18804561 0.83 DDR1 (0.81) KDRDDR1DDR2ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof XIAMEN UNIVERSITY (CN) 2022-05-03 — — US disclosed
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF XIAMEN UNIVERSITY (CN) 2020-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123162-A1 SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF CYP4A11, CYP2D6, CYP3A43 KDR 2067/4885DDR1 3948/4885DDR2 4208/4885
US-11319322-B2 Substituted aryl ether compound, preparation method thereof, pharmaceutical composition and use thereof CYP4A11, CYP2D6, CYP3A43 KDR 2067/4885DDR1 3948/4885DDR2 4208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback